Floatz logo

Tivozanib

Digestive System Cancer

Dana-Farber Cancer InstituteSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
81/ 100

Competitive context

73 Active assets in the Digestive System Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 2BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Brian Anderson, MD
Phase 4BB
DEXAMETHASONE
Cedars-Sinai Medical Center
Phase 4BB
Irinotecan
Amgen
Phase 2BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Tivozanib is also rated in:

renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →